AgeX Therapeutics Inc. (AGE) and Unum Therapeutics Inc. (NASDAQ:UMRX) Comparing side by side

Both AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Unum Therapeutics Inc. (NASDAQ:UMRX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgeX Therapeutics Inc. 3 0.00 15.30M -0.29 0.00
Unum Therapeutics Inc. 2 0.00 13.54M -1.33 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of AgeX Therapeutics Inc. and Unum Therapeutics Inc.

Profitability

Table 2 provides AgeX Therapeutics Inc. and Unum Therapeutics Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
AgeX Therapeutics Inc. 596,328,487.35% -109.8% -85.5%
Unum Therapeutics Inc. 727,917,853.88% -62.3% -43.3%

Liquidity

The Current Ratio and Quick Ratio of AgeX Therapeutics Inc. are 4.2 and 4.2 respectively. Its competitor Unum Therapeutics Inc.’s Current Ratio is 2.7 and its Quick Ratio is 2.7. AgeX Therapeutics Inc. can pay off short and long-term obligations better than Unum Therapeutics Inc.

Institutional & Insider Ownership

The shares of both AgeX Therapeutics Inc. and Unum Therapeutics Inc. are owned by institutional investors at 23.5% and 47.8% respectively. Insiders owned 0.2% of AgeX Therapeutics Inc. shares. Competitively, Unum Therapeutics Inc. has 39.76% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AgeX Therapeutics Inc. 31.39% -12.28% -35.18% -25.45% 0% -2.01%
Unum Therapeutics Inc. -11.61% -17.84% -39.26% -50% -87.48% -55%

For the past year AgeX Therapeutics Inc.’s stock price has smaller decline than Unum Therapeutics Inc.

Summary

On 5 of the 9 factors AgeX Therapeutics Inc. beats Unum Therapeutics Inc.

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.